Jianfeng Group Subsidiary Obtains Drug Registration Certificate for Tedizolid Phosphate for Injection

Jiemian··Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Jianfeng Group announced that its wholly-owned subsidiary Jianfeng Pharmaceutical has received the Drug Registration Certificate for Tedizolid Phosphate for Injection issued by the National Medical Products Administration. The drug specification is 200 mg, approved as a Category 4 chemical drug, and deemed to have passed the consistency evaluation. It is indicated for the treatment of acute bacterial skin and skin structure infections caused by susceptible isolates of Gram-positive bacteria.

Impact on assets 1

Others▲ · 1 stocks
© 2026 MarketIVNews